Cancer reports最新文献

{"title":"Mobile Health Technology Ownership and Use Among Cancer Survivors in a Health System","authors":"Shirlene D. Wang, Jing Song, Julia Pincever, Julia Frey, Payton Solk, Kristina Hasanaj, Melanie Wolter, Lauren E. Wang, Fiona Webb, Siobhan M. Phillips","doi":"10.1002/cnr2.70536","DOIUrl":"10.1002/cnr2.70536","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Physical activity (PA) is associated with improved health outcomes among cancer survivors (CS), yet PA participation and access to PA programs in cancer care are low. Mobile health (mHealth) technologies such as wearable activity trackers and smartphone lifestyle applications are promising strategies to promote PA among CS. However, CS's adoption patterns and willingness to share resulting mHealth data with healthcare providers are underexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study examined mHealth technology ownership and usage as well as willingness to share wearable data with healthcare providers among CS and identified demographic and health-related correlates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Self-reported data were collected from post treatment CS (<i>n</i> = 518; <i>M</i><sub>age</sub> = 56.5 (SD = 14.5); 54.6% female) from a large healthcare system. Univariate logistic regression models examined associations between demographic (age, sex, race/ethnicity, education, income, marital status, employment status, health status, BMI) and disease (time since diagnosis, treatment received, disease stage) characteristics and meeting PA guidelines (i.e., 150 min/week of moderate to vigorous PA) and activity tracker ownership, lifestyle app usage, and willingness to share wearable data with healthcare providers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nearly all CS (97.5%) owned a smartphone. Over half (52.9%) owned an activity tracker, and one-third (32.4%) used a lifestyle app. Most (64.3%) were willing to share wearable data with healthcare providers. Participants with a college degree or higher income, those who met PA guidelines, and those who were obese were more likely to own a wearable activity tracker. Along with those factors, younger age (< 65) and full-time employment were also associated with a higher likelihood of using a lifestyle app (<i>p</i> < 0.05). Being employed full-time was significantly associated with willingness to share data with a healthcare provider. No other relationships were significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Many CS use or are open to using mHealth technologies. However, differences in adoption by demographic characteristics and unclear demographic and disease correlates of willingness to share data highlight the need for targeted, inclusive, and evidence-based strategies to integrate these tools into survivors","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13045477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a Prognostic Risk Model for Helicobacter pylori Infection in Gastric Cancer Patients and Immunological Analysis","authors":"Zhiying Tian,&nbsp;Miao Su,&nbsp;Bin Yang,&nbsp;Zhaoyun Zhang,&nbsp;Li Zhang","doi":"10.1002/cnr2.70511","DOIUrl":"10.1002/cnr2.70511","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastric carcinoma poses a significant global health challenge, often diagnosed late due to its similarity to chronic gastric conditions. <i>Helicobacter pylori</i> (Hp) infection plays a crucial role in gastric carcinogenesis through inflammation and the release of virulent products.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aimed to identify Hp infection-related genes associated with gastric cancer prognosis and to develop a prognostic risk model that can predict patient outcomes, characterize the tumor immune microenvironment, and evaluate potential responses to immunotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>In this study, multiple GEO datasets with Hp infection were analyzed to identify genes associated with gastric cancer prognosis. A predictive risk scoring model comprising nine genes related to Hp infection and gastric cancer prognosis was constructed and validated. The prognostic model demonstrated its efficacy in predicting prognosis, correlating with clinical characteristics, functional enrichment, immune cell infiltration, genomic mutations, and immune regulator expression. Additionally, analysis of immune therapy response suggested the potential prognostic effect of markers in gastric cancer immune response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings offer valuable insights into gastric cancer diagnosis and targeted therapy, paving the way for improved patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13045470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Sequencing Strategies for Endometrial Microbiome Profiling in Endometrial Cancer: A Comparative Study of Short- and Long-Read 16S rRNA Approaches.","authors":"Sophia Bebelman, Anastasiia Artuyants, Bianca Nijmeijer, Sandra Fitzgerald, Claire Henry, Cherie Blenkiron","doi":"10.1002/cnr2.70540","DOIUrl":"10.1002/cnr2.70540","url":null,"abstract":"<p><strong>Background: </strong>Endometrial cancer (EC) is the most common gynaecological malignancy globally, with rising incidence and notable disparities in outcomes. In New Zealand, EC rates have increased significantly, particularly among Māori and Pacific women, who face higher risks of advanced disease and poorer outcomes. Microbial dysbiosis has been implicated in EC pathogenesis, but characterising the uterine microbiome is challenging due to low microbial biomass and high contamination risk.</p><p><strong>Aims: </strong>This study aimed to pilot a protocol that could inform the preparation of a larger cohort trial. Short-read Illumina MiSeq and long-read Oxford Nanopore Technologies (ONT) 16S rRNA gene sequencing were investigated to profile the uterine microbiome in people with EC.</p><p><strong>Methods and results: </strong>Uterine and vaginal swabs were analysed to assess platform performance in terms of DNA recovery, sequencing success, diversity metrics, and taxonomic resolution. The impact of sample freezing or immediate lysis prior to DNA extraction was also evaluated. ONT sequencing provided enhanced species-level resolution and improved detection of low-abundance taxa but showed variable performance in low-yield samples. Freezing prior to cell DNA extraction modestly increased bacterial 16S copy numbers and improved community consistency. Contamination was a problem across both platforms, particularly in low-biomass samples, but can be minimised during data analysis.</p><p><strong>Conclusion: </strong>This study provides practical guidance for sequencing platform selection and sample handling in uterine microbiome research. Our findings support future efforts to elucidate microbial contributions to EC pathogenesis and highlight the importance of rigorous contamination control. Importantly, this is the first presentation of a New Zealand cohort and contributes valuable data from an underrepresented population and informs future research in diverse clinical settings.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70540"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13079076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Cryoablation Under Local Anesthesia for Pulmonary Metastases From Colorectal Cancer: Long-Term Outcomes From a Single-Institution Retrospective Cohort.","authors":"Shun Yorimori, Kaoru Kaseda, Yusuke Aoki, Kosuke Sugino, Takahiro Suzuki, Yu Okubo, Shigeki Suzuki, Kyohei Masai, Masashi Tamura, Masanori Inoue, Hideki Yashiro, Seishi Nakatsuka, Yoshikane Yamauchi, Yotaro Izumi, Masafumi Kawamura, Masahiro Jinzaki, Keisuke Asakura","doi":"10.1002/cnr2.70550","DOIUrl":"10.1002/cnr2.70550","url":null,"abstract":"<p><strong>Background: </strong>Surgical resection is the standard treatment for pulmonary metastases from colorectal cancer, but its safety and long-term efficacy in medically inoperable patients remain limited. Percutaneous cryoablation is a minimally invasive alternative to surgical resection and has gained increasing attention in recent years.</p><p><strong>Aims: </strong>This retrospective study aimed to evaluate complication rates, local tumor control, and overall survival associated with percutaneous cryoablation for pulmonary metastases from colorectal cancer.</p><p><strong>Methods and results: </strong>We retrospectively reviewed patients treated with percutaneous cryoablation from 2002-2017. Complications were defined as adverse events ≥ grade 2 per Common Terminology Criteria for Adverse Events version 5.0. In total, 126 metastatic pulmonary tumors in 48 patients were treated across 73 sessions. Complications occurred in 18 sessions (24.7%), including 2 grade ≥ 3 events (2.7%). No treatment-related deaths occurred within 30 days. With a median follow-up of 9.7 months (maximum, 155.4 months), local tumor control rates at 1, 3, and 5 years were 74.5%, 58.8%, and 56.4%, respectively. Median overall survival was 3.8 years, with 1-, 3-, 5-, and 10-years rates of 86.8%, 60.4%, 41.9%, and 36.6%, respectively. The relatively short median follow-up should be considered when interpreting these long-term local control estimates. Six patients achieved 10-years survival.</p><p><strong>Conclusion: </strong>Percutaneous cryoablation is a safe, minimally invasive option that provides favorable local tumor control and encouraging long-term survival outcomes.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70550"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHI3L1 Is Associated With TP53 Signaling and Promotes Papillary Thyroid Carcinoma Progression.","authors":"Fen Cai, Ya'nan Zhou, Yeran Yang, Meng Zhang, Xuan Zhang, Yan Chang, Shengcai Wang, Xinyuan Wu, Yongli Guo, Yongbo Yu, Xin Ni, Jiangqiao Geng","doi":"10.1002/cnr2.70553","DOIUrl":"10.1002/cnr2.70553","url":null,"abstract":"<p><strong>Background: </strong>Papillary thyroid carcinoma (PTC) is the most commonly diagnosed subtype of thyroid cancer and represents a highly prevalent form of endocrine malignancy.</p><p><strong>Aims: </strong>This study aimed to investigate the role and molecular mechanism of CHI3L1 in PTC progression.</p><p><strong>Methods and results: </strong>CHI3L1 expression in PTC was analyzed using public datasets. Cell proliferation was assessed using the CCK-8 assay and colony formation assay. Tumor growth was evaluated using nude mouse xenograft models. Cell invasion was evaluated using the transwell assay, while cell migration was assessed with the wound healing assay. Transcriptomic analysis was conducted to examine the molecular mechanism, and real-time quantitative PCR was performed for gene expression validation. The findings revealed that CHI3L1 expression was upregulated in various cancers, mainly in PTC. Both in vitro and in vivo assays demonstrated that cell proliferation was suppressed when CHI3L1 was knocked down. Transcriptome sequencing indicated that CHI3L1 knockdown was associated with migration-related pathways and the TP53 signaling pathway. Transwell assays showed reduced cell invasion upon CHI3L1 suppression, while wound healing assays demonstrated decreased cell migration. Following CHI3L1 silencing, real-time quantitative PCR verified the overexpression of TP53-related genes. Survival analysis further indicated a correlation between elevated CHI3L1 expression and reduced survival rates.</p><p><strong>Conclusion: </strong>This study identified that CHI3L1 was an oncogene in PTC and promotes tumor cell proliferation associated with downregulating the TP53 pathway. It provides new evidence supporting CHI3L1 as a potential molecular target for future therapeutic investigation in PTC.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70553"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NFIB Regulates Chemoresistance in Small Cell Lung Cancer by Suppressing Notch Signaling Activity.","authors":"Weixin Qin, Ziyan Wang, Shuzhe Deng, Huilei Qiu, Hongxue Meng, Jingshu Geng","doi":"10.1002/cnr2.70526","DOIUrl":"10.1002/cnr2.70526","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung cancer (SCLC) is an aggressive malignancy characterized by the rapid development of therapy resistance, the underlying mechanisms of which remain incompletely understood. The transcription factor NFIB is a recognized oncogene in SCLC, promoting tumor progression by regulating metastasis and proliferation. However, its potential role in mediating chemotherapy resistance is poorly defined.</p><p><strong>Aims: </strong>This study aimed to elucidate the mechanism by which NFIB regulates chemoresistance in SCLC and to assess the therapeutic potential of co-targeting NFIB and the Notch signaling pathway.</p><p><strong>Methods and results: </strong>Expression of NFIB and associated genes was analyzed in SCLC cell lines and clinical samples using Western blotting, quantitative real-time PCR (qRT-PCR), immunofluorescence (IF), and immunohistochemistry (IHC). Transcriptional regulation was examined by chromatin immunoprecipitation (ChIP), and drug sensitivity was measured via CCK-8 assays. We found that NFIB acts as a dual-function regulator, driving oncogenesis and controlling chemoresistance. NFIB knockdown activated the endogenous Notch pathway, which in turn promoted drug resistance. NFIB expression positively correlated with neuroendocrine (NE) markers and contributed to tumor heterogeneity, a process modulated by Notch1. Mechanistically, loss of NFIB relieved its repression of Notch1, leading to suppressed NE gene expression and yielding slow-cycling, chemoresistant cells with activated Notch signaling. Critically, combining Notch pathway inhibition with chemotherapy attenuated intratumoral heterogeneity and reversed this resistance phenotype.</p><p><strong>Conclusions: </strong>NFIB plays a paradoxical role in SCLC, serving as both an oncogenic driver and a key regulator of chemoresistance via Notch pathway activation. These findings revealed a novel resistance mechanism and propose a promising therapeutic strategy of combined Notch inhibition and chemotherapy for SCLC treatment.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70526"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Bioinformatic Analysis of TONSL Expression in Pan-Cancer.","authors":"Ying Yang, Bolan Zhou","doi":"10.1002/cnr2.70551","DOIUrl":"10.1002/cnr2.70551","url":null,"abstract":"<p><strong>Background: </strong>TONSL is involved in various biological processes such as maintaining genomic stability and promoting tumor progression.</p><p><strong>Aims: </strong>The purpose of this article is to comprehensively clarify the expression of TONSL in Pan-Cancer, explore the association between TONSL expression and tumor tissues, prognosis, and immune infiltration in the tumor microenvironment, and clarify the interaction and combined effect between TONSL and MMS22L. This will further provide more precise targets and strategies for tumor treatment.</p><p><strong>Methods and results: </strong>Methods for evaluating immune-infiltration based on genomics and transcriptomics have become a popular area of research. This study found that TONSL is often overexpressed in tumor tissues and is linked to a poor prognosis. TONSL expression can impact immune infiltration in the tumor microenvironment and subsequently affect tumor prognosis. TONSL can interact with MMS22L to have a combined effect.</p><p><strong>Conclusion: </strong>These findings shed light on TONSL expression in Pan-Cancer comprehensively and provide more precise targets and strategies for tumor therapy.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70551"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Midgut Neuroendocrine Tumours: Are They at Higher Risk of Anastomotic Leak Than Midgut Adenocarcinomas? A Case-Control Study.","authors":"Sara-Jane Horne, Mark Coleman, Jon Bishop","doi":"10.1002/cnr2.70532","DOIUrl":"10.1002/cnr2.70532","url":null,"abstract":"<p><strong>Background: </strong>The incidence of neuroendocrine tumours is increasing; they are now the most prevalent small bowel malignancy.</p><p><strong>Aims: </strong>To identify whether primary anastomoses following resections of midgut neuroendocrine tumours (NETs) are at higher risk of anastomotic leak than primary anastomoses following midgut adenocarcinoma resections.</p><p><strong>Methods and results: </strong>Retrospective analysis of all cases of midgut NET resections and primary anastomoses at a tertiary university hospital in the UK 2019-2024, comparing these to controls of midgut adenocarcinoma resections and primary anastomoses at the same hospital during the same time period. 35 NET cases were matched with 35 adenocarcinoma controls, with anastomotic leaks in 4 (11.4%) cases and 2 (5.7%) controls. The morbidity rate was slightly higher in the NET cohort, occurring in 17 (49%) cases compared to 15 (43%) in the adenocarcinoma controls. However, the proportion of severe complications in the adenocarcinoma controls was higher. Neither of the cohorts had mortalities within 30 days of surgery. Overall all-cause mortality rates and median survival post-operatively were comparable between the two cohorts.</p><p><strong>Conclusion: </strong>NETs may be an independent risk factor for anastomotic leak rates; however, further evidence with larger cohorts of patients is required. Due to the low incidence of midgut NETs and midgut adenocarcinomas, a national collaborative is recommended.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70532"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha-Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC): A Case Report.","authors":"Kaiwen Zhong, Xiaoying Wu, Xiangling Lin, Maoyun Xie, Min Deng, Qiang Tao, Wei Qin, Songlin Peng","doi":"10.1002/cnr2.70547","DOIUrl":"https://doi.org/10.1002/cnr2.70547","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, with high rates of mortality and drug resistance. Carbohydrate antigen 19-9 (CA19-9) is a tumor biomarker for diagnosis and prognosis in PDAC. However, elevated alpha-fetoprotein (AFP) is exceedingly rare in the PDAC patient.</p><p><strong>Case presentation: </strong>Herein, we describe a 67-year-old woman who presented with elevated AFP before the diagnosis of PDAC. In March 2025, this patient who had elevated AFP and CA19-9 levels and was presenting with jaundice, was diagnosed with PDAC. Subsequently, she underwent pancreaticoduodenectomy, partial resection of the superior mesenteric vein (SMV), and SMV reconstruction. After radical resection (R0), the levels of AFP and CA19-9 were significantly decreased. Next, she was treated with adjuvant chemotherapy (gemcitabine plus capecitabine). After four cycles of treatment, the patient presented with diarrhea, weight loss, poor nutritional status, and other signs of poor tolerance to chemotherapy. Thus, the regimen was changed to pembrolizumab plus trametinib. Hepatic recurrence was detected at the 7-month follow-up. At 11 months after surgery, the patient developed a biliary tract infection and obstructive jaundice, and ultimately died.</p><p><strong>Conclusions: </strong>This case demonstrates that AFP may be a potential biomarker for PDAC, especially in the CA19-9-negative PDAC patient.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70547"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Chemopreventive Agents in the Management of Oral Potentially Malignant Disorders and Oral Cancer: A Narrative Review.","authors":"Lana Sayal, Omar Hamadah, Eyad Chatty, Anas Abdo, Sana Aghbari, Ali Munasser, Amirah Alnour","doi":"10.1002/cnr2.70559","DOIUrl":"https://doi.org/10.1002/cnr2.70559","url":null,"abstract":"<p><strong>Background: </strong>Oral squamous cell carcinoma (OSCC) is a common and aggressive cancer sometimes subsequent to oral potentially malignant disorders (OPMDs). Notwithstanding progress in surgical, radiotherapeutic, and chemotherapeutic interventions, survival rates for OSCC continue to be inadequate and are associated with significant functional impairment, underscoring the necessity for preventive and interceptive therapeutic approaches. Chemoprevention has emerged as a viable strategy to inhibit, postpone, or reverse oral carcinogenesis by targeting the molecular and cellular processes implicated in malignant transformation.</p><p><strong>Recent findings: </strong>This review synthesizes current evidence on chemopreventive agents investigated in OPMDs and OSCC. Relevant literature was analyzed focusing on natural compounds, synthetic drugs, and targeted biological therapies, as well as emerging delivery approaches. Significant emphasis is placed on bioactive phytochemicals such as retinoids, carotenoids (β-carotene and lycopene), curcumin, resveratrol, black raspberries, and vitamin E, alongside synthetic agents including cyclooxygenase-2 inhibitors and epidermal growth factor receptor (EGFR)-targeted therapies. These drugs demonstrate chemopreventive effects via modulating oxidative stress, inflammation, cell cycle regulation, apoptosis, angiogenesis, epithelial-mesenchymal transition, and immune evasion in the tumor microenvironment. Clinical and experimental investigations examined in this review reveal inconsistent, although promising results, including the regression of dysplasia, decreased rates of malignant transformation, and enhanced molecular risk profiles in OPMDs. Nonetheless, obstacles persist about long-term effectiveness, ideal dose, toxicity, and patient adherence.</p><p><strong>Conclusion: </strong>Chemopreventive medicines, especially when utilised in combination and through sophisticated delivery systems, signify a prospective adjunct or alternative approach in the care of OPMDs and OSCC, with the capacity to diminish disease burden and enhance patient outcomes.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":"e70559"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13109084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}